Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement structure/function v. disease claims distinction made in FDA proposed rules.

This article was originally published in The Tan Sheet

Executive Summary

SUPPLEMENT STRUCTURE/FUNCTION v. DISEASE CLAIMS DISTINCTION MADE by FDA in proposed rules scheduled for publication in the Federal Register the week of April 27. The agency proposal establishes the criteria both for structure/function claims allowed under the Dietary Supplement Health & Education Act and disease claims, which are prohibited for supplements. The law allows, without FDA authorization, "claims that are truthful and not misleading about the effect of a dietary supplement on the structure or function of the body for maintenance of good health and nutrition," FDA said April 24.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel